Megarozet Tab.

Ingredient

Ezetimibe/Rosuvastatin Calcium

Content

10/5mg, 10/10mg, 10/20mg

Indication

Treatment of primary hypercholesterolemia: As an adjunct to diet for the reduction of elevated total-C, LDL-C, apolipoprotein-B (apo-B), triglycerides, and non-high-density lipoprotein cholesterol (HDL-C), and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hypercholesterolemia

Menactra®

Ingredient

0.5-milliliter (mL) dose of MenQuadfi® to contain 10 µg each of meningococcal A, C, W, and Y polysaccharides conjugated to approximately 55 µg of tetanus toxoid protein carrier

Content

Indication

r active immunization to prevent invasive meningococcal
disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra
is approved for use in individuals 9 months through 55 years of age

Minjuvi™ Inj. 200mg

Ingredient

One vial of powder contains 200 mg of tafasitamab

Content

White to slightly yellowish lyophilised powder.

Indication

In combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Munobal Tab.

Ingredient

Felodipine

Content

2.5mg, 5mg

Indication

Treatment of hypertension, stable angina pectoris.